Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Chemotherapy-Induced Nausea and Vomiting
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Treatment options for patients with ovarian germ cell tumors include:
Surgery.
Chemotherapy.
Radiation therapy.
High-dose chemotherapy with bone marrow transplant (under clinical evaluation).
Patients may be treated with unilateral salpingo-oophorectomy or total abdominal hysterectomy and bilateral salpingo-oophorectomy.
All patients except those with stage I, grade I immature teratoma and stage IA dysgerminoma require postoperative chemotherapy. With platinum-based combination chemotherapy, the prognosis for patients with endodermal sinus tumors, immature teratomas, embryonal carcinomas, choriocarcinomas, and mixed tumors containing one or more of these elements has improved dramatically.[1] As new and more effective drugs are developed, many of these patients will be candidates for newer clinical trials.
Sources: 1
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Treatment options for stage I dysgerminomas include:
Unilateral salpingo-oophorectomy with or without lymphangiography or computed tomography (CT).
Unilateral salpingo-oophorectomy followed by observation.
Unilateral salpingo-oophorectomy with adjuvant radiation therapy or chemotherapy.
For patients with stage I dysgerminoma, unilateral salpingo-oophorectomy conserving the uterus and opposite ovary is accepted treatment of the younger patient who wants to preserve fertility or a pregnancy. Postoperative lymphangiography or CT is indicated before treatment decisions are made for patients who have not had careful surgical and pathological examination of pelvic and para-aortic lymph nodes during surgery.
Patients who have been completely staged and have stage IA tumors may be observed carefully after surgery without adjuvant treatment. About 15% to 25% of these patients will relapse, but they can be treated successfully at the time of recurrence with a high likelihood of cure.
Incompletely staged patients or those with higher stage tumors should probably receive adjuvant treatment. Options include radiation therapy or chemotherapy. A disadvantage of the former is loss of fertility resulting from ovarian failure. Experience with adjuvant chemotherapy is limited, but considering the effectiveness of chemotherapy in tumors other than dysgerminoma and in advanced stage dysgerminoma, adjuvant chemotherapy is likely to be very effective and to allow recovery of reproductive potential in patients with an intact ovary, fallopian tube, and uterus.[1]
Sources: 1
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Treatment options for patients with other stage I germ cell tumors include:
Unilateral salpingo-oophorectomy with adjuvant chemotherapy.
Unilateral salpingo-oophorectomy followed by observation.
For patients with stage I germ cell tumors, unilateral salpingo-oophorectomy should be performed when fertility is to be preserved. For all patients with tumors other than pure dysgerminoma and low-grade (grade I) immature teratoma, chemotherapy is usually given postoperatively, although a series demonstrated excellent survival for patients with all types of stage I tumors managed by surveillance, reserving chemotherapy for cases in which postsurgery recurrence is documented.[2][Level of evidence C1]
Sources: 2 · Level of evidence C1
There is considerable experience with a combination of vincristine, dactinomycin, and cyclophosphamide (VAC) given in an adjuvant setting. However, combinations containing cisplatin, etoposide, and bleomycin (BEP) are now preferred because of a lower relapse rate and shorter treatment time.[3] While a prospective comparison of VAC versus BEP has not been performed, in well-staged patients with completely resected tumors, relapse is rare following platinum-based chemotherapy.[3] However, the disease will recur in about 25% of well-staged patients treated with 6 months of VAC.[4]
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Treatment options for patients with stage II dysgerminomas include:
Total abdominal hysterectomy and bilateral salpingo-oophorectomy with adjuvant radiation therapy or chemotherapy.
Unilateral salpingo-oophorectomy with adjuvant chemotherapy.
Clinical trials.
For patients with stage II dysgerminoma, total abdominal hysterectomy and bilateral salpingo-oophorectomy are usually performed. For the younger patient who wants to preserve fertility, a unilateral salpingo-oophorectomy may be considered standard therapy, depending on the age of the patient, and adjuvant chemotherapy should be given.
These patients should receive adjuvant treatment. Options include radiation therapy or chemotherapy. A disadvantage of the former is loss of fertility resulting from ovarian failure. Experience with adjuvant chemotherapy is limited, but considering the effectiveness of chemotherapy in tumors other than dysgerminoma and its effectiveness in advanced-stage dysgerminoma, adjuvant chemotherapy is likely to be effective and to allow recovery of reproductive potential in patients with an intact ovary, fallopian tube, and uterus. Thus, adjuvant chemotherapy with the combination of bleomycin, etoposide, and cisplatin (BEP) has replaced radiation therapy except in the rare patient in whom chemotherapy is not considered appropriate.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Treatment options for patients with other stage II germ cell tumors include:
Unilateral salpingo-oophorectomy with adjuvant chemotherapy.
Second-look laparotomy.
Clinical trials.
For patients with stage II germ cell tumors other than pure dysgerminoma, unilateral salpingo-oophorectomy should be performed when fertility is to be preserved. Although there is considerable experience with the combination of vincristine, dactinomycin, and cyclophosphamide (VAC), especially when given in an adjuvant setting, BEP is more effective.[1-3] Patients who do not respond to a cisplatin-based combination may still attain a durable remission with VAC as salvage therapy.[4] Recurrence after three courses of BEP as adjuvant therapy is rare.[4] All patients who do not respond to standard therapy are candidates for clinical trials. When there is residual disease or elevated levels of alpha-fetoprotein or human chorionic gonadotropin after maximal surgical debulking, three or four courses of BEP combination chemotherapy are indicated.[5]
Evidence suggests that second-look laparotomy is not beneficial in patients with initially completely resected tumors who receive cisplatin-based adjuvant treatment.[6] Second-look surgery may be of benefit for a minority of patients whose tumor was not completely resected at the initial surgical procedure and who had teratomatous elements in their primary tumor.[6,7] Surgical resection of residual masses detected by clinical examination, by radiographic procedures, or at re-exploration should be undertaken since reversion to germ cell tumor has been described.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Treatment options for patients with stage III dysgerminomas include:
Total abdominal hysterectomy and bilateral salpingo-oophorectomy.
Unilateral salpingo-oophorectomy with adjuvant chemotherapy.
Clinical trials.
For patients with stage III dysgerminoma, total abdominal hysterectomy and bilateral salpingo-oophorectomy are recommended with removal of as much gross tumor as can be done safely without resection of portions of the urinary tract or large segments of the small or large bowel. Patients who want to preserve fertility may be treated with unilateral salpingo-oophorectomy if chemotherapy is to be used.[1-5]
Combination chemotherapy with bleomycin, etoposide, and cisplatin (BEP) can cure most of these patients. In a report of results from two Gynecologic Oncology Group (GOG) trials, 19 of 20 patients with incompletely resected tumors who were treated with BEP or cisplatin, vinblastine, and bleomycin (PVB) were disease free at a median follow-up of 26 months.[1] When there is bulky residual disease, it is common to give three to four courses of a cisplatin-containing combination such as PVB or BEP.[6-8] A randomized study in testicular cancer has shown that bleomycin is an essential component of the BEP regime when only three courses are given.[9] Because chemotherapy with BEP appears to be less sterilizing than wide-field radiation, combination chemotherapy is the preferred treatment in the patient who wants to preserve fertility.[1]
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Treatment options for patients with other stage III germ cell tumors include:
Total abdominal hysterectomy and bilateral salpingo-oophorectomy with adjuvant chemotherapy, with or without neoadjuvant chemotherapy.
Unilateral salpingo-oophorectomy with adjuvant chemotherapy, with or without neoadjuvant chemotherapy.
Second-look laparotomy.
Clinical trials.
For patients with stage III germ cell tumors other than pure dysgerminoma, total abdominal hysterectomy and bilateral salpingo-oophorectomy is recommended with removal of as much tumor in the abdomen and pelvis as can be done safely without resection of portions of the urinary tract or large segments of the small or large bowel. Patients who wish to preserve fertility can be treated with unilateral salpingo-oophorectomy.[1,3,4] For patients with extensive intra-abdominal disease whose clinical condition precludes debulking surgery, chemotherapy can be considered prior to surgery. Following maximal surgical debulking, three to four courses of cisplatin-containing combination chemotherapy are indicated.[2,6,10]
Evidence suggests that second-look laparotomy is not beneficial in patients with initially completely resected tumors who receive cisplatin-based adjuvant treatment.[11] Patients who do not respond to a cisplatin and etoposide-based combination may still attain a durable remission with a combination of vincristine, dactinomycin, and cyclophosphamide or a combination of cisplatin, vinblastine, and ifosfamide as salvage therapy.[6] Second-look surgery may be of benefit for a minority of patients whose tumor was not completely resected at the initial surgical procedure and who had teratomatous elements in their primary tumor.[11] Surgical resection of residual masses detected by clinical examination, by radiographic procedures, or at re-exploration should be undertaken since reversion to germ cell tumor or progressive teratoma has been described.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Treatment options for patients with stage IV dysgerminomas include:
Total abdominal hysterectomy and bilateral salpingo-oophorectomy with adjuvant chemotherapy.
Unilateral salpingo-oophorectomy with adjuvant chemotherapy.
Clinical trials.
For patients with stage IV dysgerminoma, total abdominal hysterectomy and bilateral salpingo-oophorectomy is recommended with removal of as much gross tumor in the abdomen and pelvis as can be done safely without resection of portions of the urinary tract or large segments of small or large bowel, although unilateral salpingo-oophorectomy should be considered in patients who wish to preserve fertility.[1,2] Chemotherapy with bleomycin, etoposide, and cisplatin (BEP) can cure the majority of such patients. Stage IV dysgerminoma is not treated with radiation therapy, but rather with chemotherapy, preferably with three to four courses of cisplatin-containing combination chemotherapy such as BEP.[1] A second-look operation following treatment is rarely beneficial.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Treatment options for patients with other stage IV germ cell tumors include:
Total abdominal hysterectomy and bilateral salpingo-oophorectomy with adjuvant chemotherapy with or without neoadjuvant chemotherapy.
Unilateral salpingo-oophorectomy with adjuvant chemotherapy with or without neoadjuvant chemotherapy.
Clinical trials.
For patients with stage IV germ cell tumors other than pure dysgerminoma, total abdominal hysterectomy and bilateral salpingo-oophorectomy is recommended with removal of as much tumor from the abdomen and pelvis as can be done safely without resection of the kidney or large segments of the small or large bowel. Patients who wish to preserve fertility can be treated with unilateral salpingo-oophorectomy. Following maximal surgical debulking, three to four courses of cisplatin-containing combination chemotherapy are indicated.[3,4] For patients with extensive intra-abdominal disease whose clinical condition precludes debulking surgery, chemotherapy can be considered prior to surgery. Patients who do not respond to a cisplatin and etoposide-based combination may still attain a durable remission with vincristine, dactinomycin, and cyclophosphamide or cisplatin, vinblastine, and ifosfamide as salvage therapy.[4]
Second-look surgery may be of benefit for a minority of patients whose tumor was not completely resected at the initial surgical procedure and who had teratomatous elements in their primary tumor.[5,6] Surgical resection of residual masses detected by clinical examination, by radiographic procedures, or at re-exploration should be undertaken since reversion to germ cell tumor or progressive teratoma has been described.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Treatment options for patients with recurrent dysgerminomas include:
Cisplatin-based chemotherapy has been used effectively for patients with recurrent dysgerminoma with and without adjuvant radiation therapy.[1]
Sources: 1
Patients with recurrent pure dysgerminoma of the ovary are candidates for clinical trials. Some consideration should be given to the use of high-dose regimens with rescue.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 18, 2024. Captured 2026-09-09.
Treatment options for patients with other recurrent germ cell tumors include:
Patients with recurrent germ cell tumors of the ovary other than pure dysgerminoma should be treated with chemotherapy, the type of which is determined by previous treatment.[2] Radiation therapy is not effective in this setting. Cisplatin-based combination chemotherapy is effective.[1,3,4] Patients who do not respond to a cisplatin-based combination may still attain a durable remission with vincristine, dactinomycin, and cyclophosphamide or ifosfamide and cisplatin as salvage therapy.[1] Newer potential treatments include an ifosfamide combination [5] or high-dose chemotherapy and autologous marrow rescue.[6-8] Although the role of secondary cytoreductive surgery for patients with recurrent or progressive ovarian germ cell tumors remains controversial, it may have some benefit for a select group of patients, particularly those with immature teratoma.[9] After maximal effort for surgical cytoreduction, chemotherapy should be considered.
Patients with recurrent germ cell tumors of the ovary are candidates for clinical trials. Some consideration should be given to the use of high-dose regimens with rescue.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
The prognosis and treatment options depend on:
Sources: prognosis
The type of cancer.
The size of the tumor.
The stage of cancer (whether it affects part of the ovary, involves the whole ovary, or has spread to other places in the body).
The way the cancer cells look under a microscope.
The patient’s general health.
Ovarian germ cell tumors are usually cured if found and treated early.
Sources: cured
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
The cancer may come back in the other ovary or in other parts of the body.
Sources: ovary
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
There are different types of treatment for patients with ovarian germ cell tumors.
The following types of treatment are used:
The following types of treatment are used:
Surgery
Observation
Chemotherapy
Radiation therapy
New types of treatment are being tested in clinical trials.
New types of treatment are being tested in clinical trials.
High-dose chemotherapy with bone marrow transplant
New treatment options
Treatment for ovarian germ cell tumors may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up tests may be needed.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
Different types of treatment are available for patients with ovarian germ cell tumor. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: ovarian germ cell tumor · standard · clinical trials · research study · cancer
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
Surgery is the most common treatment of ovarian germ cell tumor. A doctor may take out the cancer using one of the following types of surgery.
Sources: Surgery
Unilateral salpingo-oophorectomy: A surgical procedure to remove one ovary and one fallopian tube.
Sources: Unilateral salpingo-oophorectomy · ovary · fallopian tube
Total hysterectomy: A surgical procedure to remove the uterus, including the cervix. If the uterus and cervix are taken out through the vagina, the operation is called a vaginal hysterectomy. If the uterus and cervix are taken out through a large incision (cut) in the abdomen, the operation is called a total abdominal hysterectomy. If the uterus and cervix are taken out through a small incision (cut) in the abdomen using a laparoscope, the operation is called a total laparoscopic hysterectomy.
Sources: Total hysterectomy · uterus · cervix · vagina · vaginal · incision · abdomen · abdominal · laparoscope
Bilateral salpingo-oophorectomy: A surgical procedure to remove both ovaries and both fallopian tubes.
Sources: Bilateral salpingo-oophorectomy
Tumor debulking: A surgical procedure in which as much of the tumor as possible is removed. Some tumors cannot be completely removed.
Sources: Tumor debulking · tumor
After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
Sources: adjuvant therapy
After chemotherapy for an ovarian germ cell tumor, a second-look laparotomy may be done. This is similar to the laparotomy that is done to find out the stage of the cancer. Second-look laparotomy is a surgical procedure to find out if tumor cells are left after primary treatment. During this procedure, the doctor will take samples of lymph nodes and other tissues in the abdomen to see if any cancer is left. This procedure is not done for dysgerminomas.
Sources: chemotherapy · second-look · laparotomy · stage · cells · primary treatment · lymph nodes · tissues · dysgerminomas
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
Observation is closely watching a patient’s condition without giving any treatment unless signs or symptoms appear or change.
Sources: Observation · condition · signs · symptoms
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy). Combination chemotherapy is treatment using more than one anticancer drug. The way the chemotherapy is given depends on the type and stage of the cancer being treated.
Sources: drugs · injected · vein · systemic chemotherapy · cerebrospinal fluid · organ · cavity · regional chemotherapy · Combination chemotherapy
For more information, see Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Sources: Drugs Approved for Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Sources: x-rays · radiation · External radiation therapy
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
This summary section describes treatments that are being studied in clinical trials. It may not mention every new treatment being studied. Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
High-dose chemotherapy with bone marrow transplant is a method of giving very high doses of chemotherapy and replacing blood-forming cells destroyed by the cancer treatment. Stem cells (immature blood cells) are removed from the bone marrow of the patient or a donor and are frozen and stored. After the chemotherapy is completed, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body’s blood cells.
Sources: High-dose chemotherapy · bone marrow transplant · doses · blood · Stem cells · bone marrow · donor · infusion
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
Combination chemotherapy (the use of more than one anticancer drug) is being tested in clinical trials.
Sources: Combination chemotherapy
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment depends on whether the tumor is a dysgerminoma or another type of ovarian germ cell tumor.
Sources: tumor · dysgerminoma · ovarian germ cell tumor
Treatment of dysgerminoma may include:
Unilateral salpingo-oophorectomy with or without lymphangiography or CT scan.
Sources: Unilateral salpingo-oophorectomy · lymphangiography · CT scan
Unilateral salpingo-oophorectomy followed by observation.
Sources: observation
Unilateral salpingo-oophorectomy followed by radiation therapy.
Sources: radiation therapy
Unilateral salpingo-oophorectomy followed by chemotherapy.
Sources: chemotherapy
Treatment of other ovarian germ cell tumors may include:
unilateral salpingo-oophorectomy followed by careful observation; or
unilateral salpingo-oophorectomy, sometimes followed by combination chemotherapy.
Sources: combination chemotherapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment depends on whether the tumor is a dysgerminoma or another type of ovarian germ cell tumor.
Sources: tumor · dysgerminoma · ovarian germ cell tumor
Treatment of dysgerminoma may include:
total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by radiation therapy or combination chemotherapy; or
Sources: abdominal · hysterectomy · bilateral salpingo-oophorectomy · radiation therapy · combination chemotherapy
unilateral salpingo-oophorectomy followed by chemotherapy.
Sources: unilateral salpingo-oophorectomy · chemotherapy
Treatment of other ovarian germ cell tumors may include:
Unilateral salpingo-oophorectomy followed by combination chemotherapy.
Second-look laparotomy (surgery done after primary treatment to see if tumor cells remain).
Sources: Second-look · laparotomy · surgery · primary treatment · tumor · cells
A clinical trial of a new treatment.
Sources: clinical trial
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment depends on whether the tumor is a dysgerminoma or another type of ovarian germ cell tumor.
Sources: tumor · dysgerminoma · ovarian germ cell tumor
Treatment of dysgerminoma may include:
Total abdominal hysterectomy and bilateral salpingo-oophorectomy, with removal of as much of the cancer in the pelvis and abdomen as possible.
Sources: abdominal · hysterectomy · bilateral salpingo-oophorectomy · cancer · pelvis · abdomen
Unilateral salpingo-oophorectomy followed by chemotherapy.
Sources: Unilateral salpingo-oophorectomy · chemotherapy
Treatment of other ovarian germ cell tumors may include:
Total abdominal hysterectomy and bilateral salpingo-oophorectomy, with removal of as much of the cancer in the pelvis and abdomen as possible. Chemotherapy will be given before and/or after surgery.
Sources: surgery
Unilateral salpingo-oophorectomy followed by chemotherapy.
Second-look laparotomy (surgery done after primary treatment to see if tumor cells remain).
Sources: Second-look · laparotomy · surgery · primary treatment · tumor · cells
A clinical trial of a new treatment.
Sources: clinical trial
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment depends on whether the tumor is a dysgerminoma or another type of ovarian germ cell tumor.
Sources: tumor · dysgerminoma · ovarian germ cell tumor
Treatment of dysgerminoma may include:
Total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy, with removal of as much of the cancer in the pelvis and abdomen as possible.
Sources: abdominal · hysterectomy · bilateral salpingo-oophorectomy · chemotherapy · cancer · pelvis · abdomen
Unilateral salpingo-oophorectomy followed by chemotherapy.
Sources: Unilateral salpingo-oophorectomy
Treatment of other ovarian germ cell tumors may include:
Total abdominal hysterectomy and bilateral salpingo-oophorectomy, with removal of as much of the cancer in the pelvis and abdomen as possible. Chemotherapy will be given before and/or after surgery.
Sources: surgery
Unilateral salpingo-oophorectomy followed by chemotherapy.
Second-look laparotomy (surgery done after primary treatment to see if tumor cells remain).
Sources: Second-look · laparotomy · surgery · primary treatment · tumor · cells
A clinical trial of a new treatment.
Sources: clinical trial
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Ovarian Germ Cell Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 31, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment depends on whether the tumor is a dysgerminoma or another type of ovarian germ cell tumor.
Sources: tumor · dysgerminoma · ovarian germ cell tumor
Treatment of dysgerminoma may include:
Chemotherapy with or without radiation therapy.
Sources: Chemotherapy · radiation therapy
Treatment of other ovarian germ cell tumors may include:
Chemotherapy.
Surgery with or without chemotherapy.
Sources: Surgery
A clinical trial of high-dose chemotherapy followed by bone marrow transplant.
Sources: clinical trial · high-dose chemotherapy · bone marrow transplant
A clinical trial of a new treatment.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Chemotherapy-Induced Nausea and Vomiting
ClinicalTrials.gov recordGerm Cell Neoplasms, Testicular Neoplasms, Non Seminomatous Germ Cell Tumors, Mediastinal Neoplasms, Genital Neoplasms, Male, Genital Neoplasms, Female, Ovarian Neoplasms
ClinicalTrials.gov recordOvarian Neoplasms, Germ Cell Tumors, Immunohistochemistry
ClinicalTrials.gov recordOvarian Germ Cell Tumors
Treatment of Recurrent Ovarian Germ Cell Tumors
Treatment of Stage I Ovarian Germ Cell Tumors
Treatment of Stage II Ovarian Germ Cell Tumors
Treatment of Stage III Ovarian Germ Cell Tumors
Treatment of Stage IV Ovarian Germ Cell Tumors